Non-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Sep 17

PMID 34532293

Citations 4

Authors

Fanming Kong

Ziwei Wang

Dongying Liao

Jinhui Zuo

Hongxia Xie

Xiaojiang Li

Yingjie Jia

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the leading cause of cancer deaths in the world. At present, immunotherapy has made a great breakthrough in lung cancer treatment. A variety of immune checkpoint inhibitors have been applied into clinical practice, including antibodies targeting the programmed cell death-1, programmed cell death-ligand 1, and cytotoxic T-lymphocyte antigen 4. However, in the actual clinical process, about 30%-50% of patients still do not receive long-term benefits. Abnormal antigen presentation, functional gene mutation, tumor microenvironment, and other factors can lead to primary or secondary resistance. In this paper, we reviewed the immune mechanism of immune checkpoint inhibitor resistance, various combination strategies, and prediction of biomarkers to overcome resistance in order to accurately screen out the advantageous population, expand the beneficiary population, and enable precise and individualized medicine.

Citing Articles

LncRNA MIR31HG fosters stemness malignant features of non-small cell lung cancer via H3K4me1- and H3K27Ace-mediated GLI2 expression.

Chen W, Wang F, Yu X, Qi J, Dong H, Cui B Oncogene. 2023; 43(18):1328-1340.

PMID: 37950038 PMC: 11065682. DOI: 10.1038/s41388-023-02883-4.

The role of macrophages in non-small cell lung cancer and advancements in 3D co-cultures.

Balazova K, Clevers H, Dost A Elife. 2023; 12.

PMID: 36809334 PMC: 9943070. DOI: 10.7554/eLife.82998.

LIM-domain binding protein 2 was down-regulated by miRNA-96-5p inhibited the proliferation, invasion and metastasis of lung cancer H1299 cells.

Chu F, Xu X, Zhang Y, Cai H, Peng J, Li Y Clinics (Sao Paulo). 2022; 78:100145.

PMID: 36473369 PMC: 9727592. DOI: 10.1016/j.clinsp.2022.100145.

Evolutions in the management of non-small cell lung cancer: A bibliometric study from the 100 most impactful articles in the field.

Chen S, Qiao Y, Chen J, Li Y, Xie J, Cui P Front Oncol. 2022; 12:939838.

PMID: 36059661 PMC: 9428518. DOI: 10.3389/fonc.2022.939838.

References

Highfill S, Rodriguez P, Zhou Q, Goetz C, Koehn B, Veenstra R . Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood. 2010; 116(25):5738-47. PMC: 3031417. DOI: 10.1182/blood-2010-06-287839. View

Wang Z, Till B, Gao Q . Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells. Oncoimmunology. 2017; 6(7):e1331807. PMC: 5543863. DOI: 10.1080/2162402X.2017.1331807. View

Maj T, Wang W, Crespo J, Zhang H, Wang W, Wei S . Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat Immunol. 2017; 18(12):1332-1341. PMC: 5770150. DOI: 10.1038/ni.3868. View

Safarzadeh E, Orangi M, Mohammadi H, Babaie F, Baradaran B . Myeloid-derived suppressor cells: Important contributors to tumor progression and metastasis. J Cell Physiol. 2017; 233(4):3024-3036. DOI: 10.1002/jcp.26075. View

Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T . Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018; 5(3):376-383. PMC: 6439838. DOI: 10.1001/jamaoncol.2018.5860. View

. Another KRAS Inhibitor Holds Its Own. Cancer Discov. 2020; 10(12):OF2. DOI: 10.1158/2159-8290.CD-NB2020-098. View

Gadgeel S, Rodriguez-Abreu D, Speranza G, Esteban E, Felip E, Domine M . Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2020; 38(14):1505-1517. DOI: 10.1200/JCO.19.03136. View

Carbone D, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M . First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 376(25):2415-2426. PMC: 6487310. DOI: 10.1056/NEJMoa1613493. View

Pathak R, Pharaon R, Mohanty A, Villaflor V, Salgia R, Massarelli E . Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure. Cancers (Basel). 2021; 12(12). PMC: 7767234. DOI: 10.3390/cancers12123851. View

10.

Li J, Wang L, Chen X, Li L, Li Y, Ping Y . CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer. Oncoimmunology. 2017; 6(6):e1320011. PMC: 5486179. DOI: 10.1080/2162402X.2017.1320011. View

11.

Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R . Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; 15(5):325-340. PMC: 5921900. DOI: 10.1038/nrclinonc.2018.29. View

12.

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

13.

Dong Z, Zhong W, Zhang X, Su J, Xie Z, Liu S . Potential Predictive Value of and Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res. 2017; 23(12):3012-3024. DOI: 10.1158/1078-0432.CCR-16-2554. View

14.

Huang Y, Yuan J, Righi E, Kamoun W, Ancukiewicz M, Nezivar J . Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012; 109(43):17561-6. PMC: 3491458. DOI: 10.1073/pnas.1215397109. View

15.

Walker L, Sansom D . The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011; 11(12):852-63. DOI: 10.1038/nri3108. View

16.

Linju Yen B, Yen M, Hsu P, Liu K, Wang C, Bai C . Multipotent human mesenchymal stromal cells mediate expansion of myeloid-derived suppressor cells via hepatocyte growth factor/c-met and STAT3. Stem Cell Reports. 2013; 1(2):139-51. PMC: 3757753. DOI: 10.1016/j.stemcr.2013.06.006. View

17.

Xu W, Hiu T, Malarkannan S, Wang L . The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation. Cell Mol Immunol. 2018; 15(5):438-446. PMC: 6068175. DOI: 10.1038/cmi.2017.148. View

18.

Blank C, Enk A . Therapeutic use of anti-CTLA-4 antibodies. Int Immunol. 2014; 27(1):3-10. DOI: 10.1093/intimm/dxu076. View

19.

Singhal S, Stadanlick J, Annunziata M, Rao A, Bhojnagarwala P, OBrien S . Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer. Sci Transl Med. 2019; 11(479). PMC: 6800123. DOI: 10.1126/scitranslmed.aat1500. View

20.

Palmieri E, Gonzalez-Cotto M, Baseler W, Davies L, Ghesquiere B, Maio N . Nitric oxide orchestrates metabolic rewiring in M1 macrophages by targeting aconitase 2 and pyruvate dehydrogenase. Nat Commun. 2020; 11(1):698. PMC: 7000728. DOI: 10.1038/s41467-020-14433-7. View